000 01168 a2200349 4500
005 20250517221943.0
264 0 _c20190124
008 201901s 0 0 hun d
022 _a0019-1442
024 7 _a10.18071/isz.70.0185
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aGombos, Barbara
245 0 0 _a[Experience with natalizumab-treatment at Semmelweis University].
_h[electronic resource]
260 _bIdeggyogyaszati szemle
_cMay 2017
300 _a185-191 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAcademic Medical Centers
650 0 4 _aHumans
650 0 4 _aImmunologic Factors
_xtherapeutic use
650 0 4 _aImmunomodulation
650 0 4 _aMultiple Sclerosis
_xdiagnostic imaging
650 0 4 _aNatalizumab
_xtherapeutic use
650 0 4 _aQuality of Life
650 0 4 _aTreatment Outcome
650 0 4 _aUniversities
700 1 _aIljicsov, Anna
700 1 _aBarsi, Péter
700 1 _aHegedüs, Katalin
700 1 _aSimó, Magdolna
773 0 _tIdeggyogyaszati szemle
_gvol. 70
_gno. 5-6
_gp. 185-191
856 4 0 _uhttps://doi.org/10.18071/isz.70.0185
_zAvailable from publisher's website
999 _c28499022
_d28499022